Skip to main content
SpringerLink
Log in

Lymphoma: Diagnostic and Therapeutic Applications of Radiopharmaceuticals

  • Chapter
Diseases of the Abdomen and Pelvis 2010–2013

  • 993 Accesses

Abstract

Lymphoma is a heterogeneous family of diseases of the lymphatic system. There are two main entities, Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL), the latter emerging either from B cells or T cells. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) assisted by in-line CT (PET/CT) plays a pivotal role in patient management. HD shows high FDG uptake in close to 100% of the patients whereas FDG avidity greatly varies among patients with NHL subtypes. Aggressive lymphomas, such as diffuse large B cell lymphoma (DLBCL), the most current form of NHL, and mantle cell lymphomas (MCL) as well as Burkitt lymphomas and even plasmocytomas take up FDG very avidly. Follicular lymphomas (FL) also show high uptake in more than 90% of the cases whereas extranodal marginal zone lymphomas (MZL), such as splenic or mucosaassociated lymphoid tissue (MALT) MZL, are positive in only 67 and 54%, respectively [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Weiler-Sagie M, Bushelev O, Epelbaum R et al (2010) 18FFDG avidity in lymphoma readdressed: A study of 766 patients. J Nucl Med 51:25–30

    Article  PubMed  Google Scholar 

  2. Hutchings M, Loft A, Hansen M et al (2006) Different histopathological subtypes of Hodgkin’s lymphoma show significantly different levels of FDG uptake. Hematol Oncol 24:146–150

    Article  CAS  PubMed  Google Scholar 

  3. Schoder H, Noy A, Gonen M et al (2005) Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 23:4643–4651

    Article  PubMed  Google Scholar 

  4. Yi JH, Kim SJ, Choi JY (2009) (18)F-FDG uptake and its clinical relevance in primary gastric lymphoma. Hematol Oncol Epub

    Google Scholar 

  5. Lee WK, Lau EW, Duddalwar VA et al (2008) Abdominal manifestations of extranodal lymphoma: spectrum of imaging findings. AJR Am J Roentgenol 191:198–206

    Article  PubMed  Google Scholar 

  6. Tateishi U, Terauchi T, Inoue T, Tobinai K (2009) Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: PET/CT. Abdom Imaging Epub

    Google Scholar 

  7. Hoffmann M, Wohrer S, Becherer A et al (2006) 18F-Fluorodeoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol 17:1761–1765

    Article  CAS  PubMed  Google Scholar 

  8. Perry C, Herishanu Y, Metzer U et al (2007) Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol 79:205–209

    Article  PubMed  Google Scholar 

  9. Raderer M, Wohrer S, Streubel B et al (2006) Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 24:3136–3141

    Article  PubMed  Google Scholar 

  10. Takahashi H, Ukawa K, Ohkawa N et al (2009) Significance of (18)F-2-deoxy-2-fluoro-glucose accumulation in the stomach on positron emission tomography. Ann Nucl Med 23:391–397

    Article  PubMed  Google Scholar 

  11. Wong MT, Eu KW (2006) Primary colorectal lymphomas. Colorectal Dis 8:586–591

    Article  CAS  PubMed  Google Scholar 

  12. Civardi G, Vallisa D, Berte R et al (2002) Focal liver lesions in non-Hodgkin’s lymphoma: investigation of their prevalence, clinical significance and the role of Hepatitis C virus infection. Eur J Cancer 38:2382–2387

    Article  CAS  PubMed  Google Scholar 

  13. Hadithi M, Mallant M, Oudejans J et al (2006) 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med 47:1622–1677

    PubMed  Google Scholar 

  14. Zafar SY, Howell DN, Gockerman JP (2008) Malignancy after solid organ transplantation: an overview. Oncologist 13:769–778

    Article  PubMed  Google Scholar 

  15. Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin’s lymphoma. Blood 107:52–59

    Article  CAS  PubMed  Google Scholar 

  16. Jerusalem G, Beguin Y, Fassotte MF et al (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica 85:613–618

    CAS  PubMed  Google Scholar 

  17. Mikhaeel NG, Hutchings M, Fields PA et al (2005) FDG-PET after two to three cycles of chemotherapy predicts progressionfree and overall survival in high-grade non-Hodgkin’s lymphoma. Ann Oncol 16:1514–1523

    Article  CAS  PubMed  Google Scholar 

  18. Mikhaeel NG, Timothy AR, O’Doherty MJ et al (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin’s Lymphoma-comparison with CT. Leuk Lymphoma 39:543–553

    CAS  PubMed  Google Scholar 

  19. Spaepen K, Stroobants S, Dupont P et al (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 13:1356–1363

    Article  CAS  PubMed  Google Scholar 

  20. Brepoels L, Stroobants S, De Wever W et al (2007) Aggressive and indolent non-Hodgkin’s lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma 48:1522–1530

    Article  PubMed  Google Scholar 

  21. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579–586

    Article  PubMed  Google Scholar 

  22. Juweid ME, Wiseman GA, Vose JM et al (2005) Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23:4652–4661

    Article  PubMed  Google Scholar 

  23. Engles JM, Quarless SA, Mambo E et al (2006) Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med 47: 603–608

    CAS  PubMed  Google Scholar 

  24. Rodriguez-Vigil B, Gomez-Leon N, Pinilla I et al (2006) PET/CT in lymphoma: prospective study of enhanced fulldose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 47:1643–1648

    PubMed  Google Scholar 

  25. Schaefer NG, Hany TF, Taverna C et al (2004) Non-Hodgkin’s lymphoma and Hodgkin’s disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?. Radiology 232:823–829

    Article  PubMed  Google Scholar 

  26. Horning SJ, Juweid ME, Schoder H et al (2009) Interim positron emission tomography (PET) scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood Epub

    Google Scholar 

  27. Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–578

    Article  PubMed  Google Scholar 

  28. Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626–1632

    Article  PubMed  Google Scholar 

  29. Sugawara Y, Zasadny KR, Kison PV et al (1999) Splenic fluorodeoxyglucose uptake increased by granulocyte colonystimulating factor therapy: PET imaging results. J Nucl Med 40:1456–1462

    CAS  PubMed  Google Scholar 

  30. Brepoels L, Stroobants S, Verhoef G (2007) PET and PET/CT for response evaluation in lymphoma: current practice and developments. Leuk Lymphoma 48:270–282

    Article  CAS  PubMed  Google Scholar 

  31. Hutchings M, Barrington SF (2009) PET/CT for therapy response assessment in lymphoma. J Nucl Med 50 Suppl 1: 21S–30S

    Article  CAS  PubMed  Google Scholar 

  32. Kobe C, Dietlein M, Franklin J et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin’s lymphoma. Blood 112:3989–3994

    Article  CAS  PubMed  Google Scholar 

  33. Kaminski MS, Tuck M, Estes J et al (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441–449

    Article  CAS  PubMed  Google Scholar 

  34. Morschhauser F, Illidge T, Huglo D et al (2007) Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110:54–58

    Article  CAS  PubMed  Google Scholar 

  35. Sharkey RM, Brenner A, Burton J et al (2003) Radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab) do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 44:2000–2018

    CAS  PubMed  Google Scholar 

  36. Witzig TE, Gordon LI, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463

    Article  CAS  PubMed  Google Scholar 

  37. Buchegger F, Antonescu C, Bischof Delaloye A et al (2006) Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin’s lymphoma. Br J Cancer 94:1770–1776

    Article  CAS  PubMed  Google Scholar 

  38. Fisher RI, Kaminski MS, Wahl RL et al (2005) Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with lowgrade and transformed non-Hodgkin’s lymphomas. J Clin Oncol 23:7565–7573

    Article  CAS  PubMed  Google Scholar 

  39. Witzig TE, Molina A, Gordon LI et al (2007) Long-term responses in patients with recurring or refractory B-cell non-Hodgkin’s lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 109:1804–1810

    Article  CAS  PubMed  Google Scholar 

  40. Buchegger F, Press OW, Delaloye AB, Ketterer N (2008) Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. Oncologist 13:657–667

    Article  PubMed  Google Scholar 

  41. Morschhauser F, Radford J, Van Hoof A et al (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156–5164

    Article  CAS  PubMed  Google Scholar 

  42. Bischof Delaloye A, Antonescu C, Louton T et al (2009) Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. J Nucl Med 50:1837–1843

    Article  Google Scholar 

  43. Gisselbrecht C, Vose J, Nademanee A et al (2009) Radioimmunotherapy for stem cell transplantation in non-Hodgkin’s lymphoma: in pursuit of a complete response. Oncologist 14 Suppl 2:41–51

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Médecine Nucléaire, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

    Angelika Bischof Delaloye

Authors
  1. Angelika Bischof Delaloye
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Radiology, University Hospital, Zurich, Switzerland

    J. Hodler

  2. Kilchberg/Zurich, Switzerland

    Ch. L. Zollikofer

  3. Nuclear Medicine, University Hospital, Zurich, Switzerland

    G. K. Von Schulthess

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Verlag Italia

About this chapter

Cite this chapter

Delaloye, A.B. (2010). Lymphoma: Diagnostic and Therapeutic Applications of Radiopharmaceuticals. In: Hodler, J., Zollikofer, C.L., Von Schulthess, G.K. (eds) Diseases of the Abdomen and Pelvis 2010–2013. Springer, Milano. https://doi.org/10.1007/978-88-470-1637-8_27

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1637-8_27

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1636-1

  • Online ISBN: 978-88-470-1637-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation